http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110232978-B

Outgoing Links

Predicate Object
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B20-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B20-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B25-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H70-40
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16H70-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B25-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B20-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B20-20
filingDate 2019-06-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2022-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2022-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-110232978-B
titleOfInvention Multidimensional network-based therapeutic drug prediction method for cancer cell lines
abstract The invention discloses a multi-dimensional network-based method for predicting therapeutic drugs of cancer cell lines, which mainly solves the problem of low accuracy of the prediction results of therapeutic drugs for cancer cell lines in the prior art. The scheme is: download the data of n cancer cell lines to construct a cancer cell line similarity network; download the data of m drugs to construct a drug similarity network; in the cancer cell line similarity network, use the diffusion component analysis algorithm to calculate Low-dimensional eigenvector matrix of n cancer cell lines; low-dimensional eigenvector matrix of m drugs is calculated using diffusion component analysis algorithm in drug similarity network; logistic regression model of drug response is obtained; drug and cancer cell lines are calculated The scores of the sensitivity relationship are between them; whether the drug has a therapeutic effect on the cancer cell line is judged by the sensitivity relationship score. The invention improves the accuracy of the prediction result of the cancer cell line therapeutic drug, and can be used for the prediction experiment of the cancer's response to the drug.
priorityDate 2019-06-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2908132-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010056893-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID44182295
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419552268
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11626560
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419475193
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426228482
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID414652573
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID216239
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID16722836

Total number of triples: 26.